Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that AA-PRP injections significantly increased hair count and density in individuals with pattern hair loss compared to baseline, demonstrating their potential for enhancing hair growth.

This review evaluates various kits for isolating platelet-rich plasma using established processing standards and finds they enable compliance with consensus quality criteria; ongoing research is needed to refine these procedures for improved consistency and safety.

In this study, autologous non-activated platelet-rich plasma was associated with greater hair re-growth than autologous activated platelet-rich plasma over long-term follow-up.

AA-PRP temporarily increases hair density in androgenetic alopecia but loses effectiveness over time.

AA-PRP injections significantly promote hair growth but need better study design for clear efficacy.

This systematic review and meta-analysis found that activated platelet-rich plasma was significantly effective and safe in improving hair density and reducing hair loss in alopecia patients compared to control groups.

This case report describes a patient with corticosteroid-resistant ophiasis alopecia areata who experienced prompt hair regrowth after receiving platelet-rich plasma injections.

This review reports that while platelet-rich plasma shows promise as a safe treatment for various types of hair loss, variability in studies limits definitive conclusions on its effectiveness.

This study found that platelet-rich plasma may improve patient-reported outcomes for scar symptoms like pain and itching at six months, although no significant changes in scar appearance were observed at three months.

This study found that intradermal injections of platelet-rich plasma were equally safe and effective for treating androgenetic alopecia, with higher platelet numbers possibly enhancing hair density and follicle diameter.

In this study, significant improvements in skin density and thickness, especially around the lower eyelid, were observed across all age groups using plasma fractions from a single blood draw, indicating that the therapy's effectiveness may be age-independent.

This study observed that autologous platelet-rich plasma treatment improved hair count and density in areas with androgenetic alopecia compared to placebo, with differing outcomes based on the PRP collection device used.

This study found that a PRP-like cosmetic product called TR-M-PRP plus significantly improved hair growth in individuals with alopecia areata over three months, as measured by the SALT score, suggesting it could be a safer alternative to traditional PRP treatments.

This study found that a standardized PRP application protocol was effective as a coadjuvant therapy in most patients with androgenetic alopecia who did not respond to minoxidil or finasteride, based on improvements in Ebling's scale.

This study found that trichoscopy aided in assessing treatment responses for patchy alopecia areata, with both intralesional corticosteroids and platelet-rich plasma showing effectiveness, but only PRP significantly improved patient symptom impact scores.

This review discusses the potential of PRP treatment for alopecia areata, highlighting reported hair growth improvements but notes the need for randomized clinical trials to confirm efficacy.

In this case study, a 29-year-old man with alopecia areata experienced satisfactory hair regrowth after five months of combined intralesional triamcinolone acetonide and platelet-rich plasma therapy.

This review discusses current topical treatments, natural products, and complementary therapies for androgenetic alopecia, but it reports no new clinical results.

This study found that intralesional corticosteroids remain the preferred treatment for alopecia areata with limited involvement, while platelet-rich plasma showed promise, particularly in children and extensive cases.

This source reports that platelet-rich plasma may be as effective as intralesional corticosteroids for treating patchy alopecia areata, with potential for earlier and more sustained results, while promising in vitro and animal studies on stem cells highlight the need for more clinical research.

PRP preparation partially activates platelets, causing varied growth factor release.

This paper reviews the autoimmune disorder alopecia areata, its progression, and its significant emotional and psychological impact, but reports no new clinical findings.

In this study conducted at Al-Azhar University Hospital, 60% of patients with localized alopecia areata responded to treatment with autologous platelet-rich plasma, with 89% of responders showing substantial improvement, suggesting PRP as an effective treatment option for this condition.

This study found that centrifugally spun scaffolds with higher concentrations of platelet-derived bioactive molecules enhanced melanocyte metabolic activity and proliferation, suggesting potential for improving vitiligo treatment.

This review highlights exosomes as a promising treatment for skin damage from UV light, infrared radiation, burns, and disorders due to their anti-inflammatory properties, ability to induce macrophage polarization, and acceleration of skin repair and regeneration.

This study found that combining PRP with topical minoxidil or finasteride significantly improved hair density and thickness, with patient satisfaction highest for multiple treatment combinations and longer durations.

This review suggests that while platelet-rich plasma has the most robust clinical evidence, platelet-rich fibrin and concentrated growth factors are gaining favor due to their ease of use and absence of additives.

This review discusses the use of non-transfusional hemocomponents in surgical procedures for tissue regeneration and reports no new empirical findings.

This review outlines the optimization of platelet concentrates for hair loss treatment and suggests extracellular vesicles as a key future element, aiming to advance point-of-care regenerative therapies despite the need for a unified framework and further research on underlying mechanisms.

This review found that hair transplantation in patients with primary cicatricial alopecias is a viable option when the disease is stable, with outcomes varying significantly by subtype.